Pfizer announced revenue of 3.5 billion USD from Vaccine Covid-19 in the first three months of the year, of which profits could reach 900 million USD.

Revenue from Vaccine Covid-19 in the first quarter accounted for nearly a quarter of Pfizer's total revenue, according to the report announced by the US pharmaceutical company today.

Therefore, pre-tax profit from the Covid-19 vaccine in the first quarter of Pfizer was estimated to reach 900 million USD.

However, the actual profit of Pfizer is said to be much higher, because they also share Vaccine Covid-19 revenue with Biontech partner of Germany, the company will report business results in the next week

Pfizer-Bionech's Covid-19 vaccine vials are on display in Ludwigsburg, Germany, on January 22.

Vaccine Covid-19 is expected to continue to bring huge revenue to Pfizer and Biontech, especially when people have the ability to repeat often.

Unlike some competitors companies claiming to earn profits from Vaccine Covid-19, Pfizer right from the beginning to determine the production of vaccines for profit, but are committed to ensuring the right to access the vaccine for the globe.

However, Pfizer's Sharon Castillo spokesman did not indicate how much dose to poor countries, where Pfizer declared non-profit.

Meanwhile, data of the World Health Organization (WHO) shows that Pfizer only supports the minimum for the poorest countries in the world.

Some people also wondered if Pfizer was vague about profits from Vaccine Covid-19.

The experts raised a number of reasons why Pfizer's vaccine is distributed uneven in the world, including storage and transport temperatures that must be extremely low, leading to a difficult vaccine to reach distant places.